November 28, 2025

How bacteria can cause cancer: Research award for Jens Puschhof

How bacteria can cause cancer: Research award for Jens Puschhof

Jens Puschhof, junior research group leader at the German Cancer Research Center (DKFZ), receives the 2026 Research Award from the Peter and Traudl Engelhorn Foundation. The foundation honors the young scientist for his research on the influence of bacteria on the development and spread of cancer.

Source: Jung/DKFZ

Jens Puschhof is analyzing the close interactions between tumor cells, healthy body cells, the immune system, and microorganisms. He has been able to show how certain bacteria directly damage genetic material, triggering mutations that can contribute to the development of colon cancer. To do this he uses innovative patient-specific organoid and organ-on-chip models, into which he introduces living bacteria and bacterial metabolites. In these models, he deciphers the underlying mechanisms of cancer-microbiome interaction in order to answer questions such as: How and when do mutations occur? Which signaling pathways change in cancer cells? Do these changes accelerate the development of colorectal cancer?

Puschhof and his team then validate the results of this analysis in mice and link them to clinical data to determine their significance for the prevention, prognosis, and treatment of colorectal cancer.

With the help of artificial intelligence (AI), the bacteria-induced mutation patterns can be detected with increasing accuracy in patient samples. There are clear indications of a link with the increasing incidence of colorectal cancer in younger age groups. Puschhof is currently investigating these patterns in the BACTORG consortium he heads, in which six university hospitals are participating.

After studying molecular biotechnology and oncology in Heidelberg, Harvard, and Oxford, Jens Puschhof moved to the University of Utrecht to work in Hans Clevers’ laboratory for his PhD thesis. Since 2022, he has headed a team in the Microbiome and Cancer Department at the DKFZ, which was converted into an independent junior research group in 2024. In 2023, Puschhof was awarded the Young Scientist Award for Cancer Prevention Research. In 2024, he received one of the prestigious Starting Grants from the European Research Council (ERC).

In 2026, the Peter and Traudl Engelhorn Foundation will exceptionally award its research award to two young scientists: In addition to Jens Puschhof from the DKFZ, Martin Pacesa from EPFL Lausanne will receive the prize for the development of open-source platforms for computer-aided protein design. Both scientists will receive prize money of 10,000 euros each for their outstanding achievements. The prizes will be presented on January 10, 2026, at the Manfred Eigen Winter Seminar in Klosters (Switzerland).

The aim of the Peter and Traudl Engelhorn Foundation is to promote young scientists in the life sciences. To this end, the foundation awards postdoctoral fellowships to outstanding young scientists. In addition, every two years it awards the Peter and Traudl Engelhorn Foundation Research Prize to young scientists who have achieved outstanding success in a highly topical field of research in Germany, Austria, or Switzerland.

A photo of Jens Puschhof is available for download: https://www.dkfz.de/fileadmin/user_upload/Skoe/Pressemitteilungen/2025/Puschhof.jpg

Note on use of images related to press releases 
Use is free of charge. The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) permits one-time use in the context of reporting about the topic covered in the press release. Images have to be cited as follows: “Source: Jung/DKFZ”.
Distribution of images to third parties is not permitted unless prior consent has been obtained from DKFZ’s Press Office (phone: ++49-(0)6221 42 2854, E-mail: presse(at)dkfz.de). Any commercial use is prohibited. 

Our latest News

discover more
AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

AbbVie Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma

NORTH CHICAGO, Ill., July 6, 2026 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced that the European Commission (EC) granted marketing authorization for TEPKINLY® (epcoritamab) in combination with lenalidomide and rituximab (TEPKINLY + R2) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). The approval is based on results from the pivotal Phase 3 […]

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

Optimized Formula: New Bio-Ink Can Depict the Cell Environment Even More Accurately

It should be biofunctional – that is, it should replicate the natural cellular environment as closely as possible – and it should be printable: bioink. Achieving both of these properties at the same time is an enormous challenge that conventional biomaterials often fail to meet. Together with two partner companies, researchers at the NMI have now taken an important […]

New AI System Provides Treatment Recommendations for Complex Blood Cancers

New AI System Provides Treatment Recommendations for Complex Blood Cancers

Researchers from the German Cancer Research Center (DKFZ), the HI-STEM* Stem Cell Institute, and the Heidelberg University Hospital (UKHD) have developed “HemaGuide,” an AI assistant that supports physicians in making difficult treatment decisions. In extensive testing, the system has shown a high degree of agreement with the recommendations of experienced experts and could significantly improve […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp